AU4135599A - Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine - Google Patents

Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine Download PDF

Info

Publication number
AU4135599A
AU4135599A AU41355/99A AU4135599A AU4135599A AU 4135599 A AU4135599 A AU 4135599A AU 41355/99 A AU41355/99 A AU 41355/99A AU 4135599 A AU4135599 A AU 4135599A AU 4135599 A AU4135599 A AU 4135599A
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
lamivudine
zidovudine
abacavir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU41355/99A
Other languages
English (en)
Inventor
Robin Currie
Sunil Jain
Allen Wayne Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU4135599A publication Critical patent/AU4135599A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU41355/99A 1998-04-29 1999-04-26 Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine Abandoned AU4135599A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9809213 1998-04-29
GBGB9809213.3A GB9809213D0 (en) 1998-04-29 1998-04-29 Pharmaceutical compositions
PCT/EP1999/002794 WO1999055372A1 (en) 1998-04-29 1999-04-26 Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine

Publications (1)

Publication Number Publication Date
AU4135599A true AU4135599A (en) 1999-11-16

Family

ID=10831228

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41355/99A Abandoned AU4135599A (en) 1998-04-29 1999-04-26 Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine

Country Status (23)

Country Link
EP (1) EP1083932A1 (id)
JP (1) JP2002512979A (id)
KR (1) KR20010043128A (id)
CN (1) CN1411380A (id)
AP (1) AP2000001971A0 (id)
AU (1) AU4135599A (id)
BR (1) BR9910071A (id)
CA (1) CA2330391A1 (id)
EA (1) EA200000997A1 (id)
EE (1) EE200000646A (id)
GB (1) GB9809213D0 (id)
HR (1) HRP20000732A2 (id)
HU (1) HUP0101622A3 (id)
ID (1) ID26955A (id)
IL (1) IL139181A0 (id)
IS (1) IS5675A (id)
NO (1) NO20005418L (id)
NZ (1) NZ507745A (id)
PL (1) PL343710A1 (id)
SK (1) SK16212000A3 (id)
TR (1) TR200003157T2 (id)
WO (1) WO1999055372A1 (id)
ZA (1) ZA200005922B (id)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
CA2374198A1 (en) * 1998-05-29 1999-12-02 Maki Arai Combination therapy for treatment of fiv infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AU2002311622A1 (en) * 2002-04-23 2003-11-10 Lupin Limited Long acting compositions comprising zidovudine and lamivudine
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
CN100335125C (zh) * 2003-06-03 2007-09-05 上海现代药物制剂工程研究中心 杀毒抗菌用长效干扰素喷鼻粉剂
WO2006114709A1 (en) * 2005-04-25 2006-11-02 Aurobindo Pharma Limited Pharmaceutical compositions of antiretrovirals
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
ES2279707B1 (es) * 2005-11-10 2008-06-01 Combino Pharm, S.L. Formulaciones orales que comprenden 3'-azidonucleosidos.
BRPI0816498A2 (pt) * 2007-10-02 2019-02-26 Emory University combinações potentes de zidovudina e drogas que selecionam para a mutuação k65r na polimerase do hiv
US20110117193A1 (en) * 2008-01-17 2011-05-19 Duquesne University Of The Holy Spirit Antiretroviral drug formulations for treatment of children exposed to hiv/aids
PE20121524A1 (es) * 2010-01-27 2012-12-03 Viiv Healthcare Co Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
IN2014MN01907A (id) 2012-03-05 2015-07-10 Cipla Ltd
CA2885763C (en) 2012-10-23 2021-04-06 Cipla Limited Pharmaceutical antiretroviral composition
SG10201910773VA (en) 2013-06-13 2020-01-30 Akebia Therapeutics Inc Compositions and methods for treating anemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
ZA200005922B (en) 2001-10-23
JP2002512979A (ja) 2002-05-08
CN1411380A (zh) 2003-04-16
NO20005418L (no) 2000-11-29
HUP0101622A2 (hu) 2002-03-28
IL139181A0 (en) 2001-11-25
NO20005418D0 (no) 2000-10-27
ID26955A (id) 2001-02-22
AP2000001971A0 (en) 2000-12-31
GB9809213D0 (en) 1998-07-01
HUP0101622A3 (en) 2003-09-29
HRP20000732A2 (en) 2001-02-28
TR200003157T2 (tr) 2001-01-22
PL343710A1 (en) 2001-08-27
CA2330391A1 (en) 1999-11-04
IS5675A (is) 2000-10-20
BR9910071A (pt) 2000-12-26
EP1083932A1 (en) 2001-03-21
KR20010043128A (ko) 2001-05-25
EA200000997A1 (ru) 2001-06-25
NZ507745A (en) 2004-07-30
WO1999055372A1 (en) 1999-11-04
EE200000646A (et) 2002-04-15
SK16212000A3 (sk) 2001-07-10

Similar Documents

Publication Publication Date Title
AU4135599A (en) Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine
EP1583542B1 (en) Compositions and methods for combination antiviral therapy
CA2633603C (en) Pharmaceutical combination
CN1185110A (zh) 协同组合物
US6113920A (en) Pharmaceutical compositions
EP0941100B1 (en) Pharmaceutical compositions containing lamivudine and zidovudine
ES2286471T3 (es) Composiciones farmaceuticas antivirales.
US20050171127A1 (en) Pharmaceutical compositions comprising abacavir and lamivudine
MXPA00010498A (en) Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine
CZ20003998A3 (cs) Farmaceutický prostředek
JP2001525839A (ja) 炭素環式ヌクレオシド１５９２ｕ８９を含有する抗ウイルス的組合せ
JP2002526449A (ja) ラミブジンおよびアバカビルを含んでなる抗ウイルス性組合せ製剤
HK1020880B (en) Pharmaceutical compositions containing lamivudine and zidovudine
MXPA99004025A (en) Pharmaceutical compositions containing lamivudine and zidovudine
CA2289654A1 (en) Antiviral combinations containing the carbocyclic nucleoside 1592u89
MXPA01002673A (en) Antiviral combinations
MX2008007776A (en) Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted